novo oral glp-1 US FDA accepts Nordisk's application for Wegovy for weight loss Novo Nordisk Could Win the

This study compared cardiovascular outcomes of tirzepatide (a dual incretin agonist) versus dulaglutide in patients with type 2 diabetes and established atherosclerotic cardiovascular disease

Increased muscarinic responsiveness and decreased muscarinic receptor content in ileal smooth muscle in diabetes

Mounjaro: 235500 per month (private) Wegovy: 170300 per month Ozempic: 150200 per month (for diabetes dosing) Private clinics are often the main route for non-diabetic weight management

Lack of sleep can interfere with your bodys hunger hormones, leading to increased appetite and weight gain

30 While GLP1RAs appear to be psychiatrically safe in this population, definitive evidence of therapeutic benefit remains lacking